SVRA vs. KMPH, GLSI, STSA, SYBX, PPBT, BHC, VERA, DCPH, MRVI, and AMRX
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Zevra Therapeutics (KMPH), Greenwich LifeSciences (GLSI), Satsuma Pharmaceuticals (STSA), Synlogic (SYBX), Purple Biotech (PPBT), Bausch Health Companies (BHC), Vera Therapeutics (VERA), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and Zevra Therapeutics (NASDAQ:KMPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Savara has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -328.56%. Zevra Therapeutics' return on equity of -16.12% beat Savara's return on equity.
Savara presently has a consensus price target of $9.17, suggesting a potential upside of 131.48%.
87.9% of Savara shares are held by institutional investors. Comparatively, 19.4% of Zevra Therapeutics shares are held by institutional investors. 5.1% of Savara shares are held by company insiders. Comparatively, 1.1% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Savara has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
In the previous week, Savara had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Savara and 0 mentions for Zevra Therapeutics. Savara's average media sentiment score of 0.00 equaled Zevra Therapeutics'average media sentiment score.
Zevra Therapeutics received 57 more outperform votes than Savara when rated by MarketBeat users. However, 66.06% of users gave Savara an outperform vote while only 62.96% of users gave Zevra Therapeutics an outperform vote.
Zevra Therapeutics has higher revenue and earnings than Savara.
Summary
Savara and Zevra Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
